1. Home
  2. PHVS vs EDN Comparison

PHVS vs EDN Comparison

Compare PHVS & EDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHVS
  • EDN
  • Stock Information
  • Founded
  • PHVS 2015
  • EDN 1992
  • Country
  • PHVS Switzerland
  • EDN Argentina
  • Employees
  • PHVS N/A
  • EDN N/A
  • Industry
  • PHVS Biotechnology: Pharmaceutical Preparations
  • EDN Electric Utilities: Central
  • Sector
  • PHVS Health Care
  • EDN Utilities
  • Exchange
  • PHVS Nasdaq
  • EDN Nasdaq
  • Market Cap
  • PHVS 980.9M
  • EDN 1.2B
  • IPO Year
  • PHVS 2021
  • EDN 2007
  • Fundamental
  • Price
  • PHVS $22.99
  • EDN $25.11
  • Analyst Decision
  • PHVS Buy
  • EDN
  • Analyst Count
  • PHVS 6
  • EDN 0
  • Target Price
  • PHVS $37.17
  • EDN N/A
  • AVG Volume (30 Days)
  • PHVS 59.1K
  • EDN 84.9K
  • Earning Date
  • PHVS 08-13-2025
  • EDN 08-05-2025
  • Dividend Yield
  • PHVS N/A
  • EDN N/A
  • EPS Growth
  • PHVS N/A
  • EDN N/A
  • EPS
  • PHVS N/A
  • EDN 0.21
  • Revenue
  • PHVS N/A
  • EDN $2,097,707,542.00
  • Revenue This Year
  • PHVS N/A
  • EDN $51.74
  • Revenue Next Year
  • PHVS N/A
  • EDN N/A
  • P/E Ratio
  • PHVS N/A
  • EDN $6.20
  • Revenue Growth
  • PHVS N/A
  • EDN 37.57
  • 52 Week Low
  • PHVS $11.51
  • EDN $13.78
  • 52 Week High
  • PHVS $26.33
  • EDN $51.69
  • Technical
  • Relative Strength Index (RSI)
  • PHVS 67.31
  • EDN 37.09
  • Support Level
  • PHVS $17.63
  • EDN $24.23
  • Resistance Level
  • PHVS $26.33
  • EDN $28.46
  • Average True Range (ATR)
  • PHVS 1.70
  • EDN 1.33
  • MACD
  • PHVS 0.65
  • EDN 0.01
  • Stochastic Oscillator
  • PHVS 65.24
  • EDN 18.44

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

About EDN Empresa Distribuidora Y Comercializadora Norte S.A. (Edenor)

Empresa Distribuidora y Comercializadora Norte SA is engaged in the distribution and sale of electricity. The firm's concession area covers the northern portion of the city of Buenos Aires mainly to residential, commercial, industrial, and public service.

Share on Social Networks: